

**clobetasol propionate 0.05% cutaneous foam
(Clarelux[®])**

(No. 280/06)

3M Health Care Ltd
Product Update

9 June 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Clobetasol propionate 0.05% cutaneous foam (Clarelux[®]) is accepted for use within NHS Scotland for short-course treatment of steroid responsive dermatoses of the scalp such as psoriasis, which do not respond satisfactorily to less potent steroids.

It offers an alternative to other scalp applications of clobetasol propionate at a similar cost (depending on the rate of application).

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 12 April 2006.

**Chairman,
Scottish Medicines Consortium**